MODEL-AD

MODEL-AD is an effort to generate and characterize fifty new mouse models of late onset Alzheimer’s disease to improve AD target discovery and validation efforts.

MODEL-AD

The MODEL-AD (Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease) consortia is a group of researchers focused on rigorous generation and characterization of fifty new mouse models of late onset Alzheimer’s disease. Alzheimer’s disease (AD) is a debilitating illness with no known disease modifying therapy.  Furthermore, 99.3% of phase III clinical trials have failed for AD drug discovery.

The goal of the MODEL-AD consortia is to improve target discovery and validation efforts in AD by creating a community resource of mouse models that closely reflect the sporadic late-onset human form of AD. As such, the consortia has focused on human AD genetics and systems biology resources such as Accelerating Medicine Partnership for AD (AMP-AD), AD Sequencing Project (ADSP), and AD Neuroimaging Initiative (ADNI) to prioritize specific variants to introduce into the mice to capture different aspects of the disease.  All data – including ‘omics, imaging, and drug treatment –  generated on the mouse models are actively distributed to the AD research community and public via the AMP-AD Knowledge Portal.


Other Collaborative Science research studies

Accelerating Medicine Partnership in Alzheimer’s Disease

AMP-AD is a public private partnership designed to use systems biology to identify novel targets for AD treatment.

Learn More

The ICGC-TCGA Whole Genome Pan-Cancer Analysis Working Group

The Pan-Cancer Analysis of Whole Genomes (PCAWG) is an effort to combine all ICGC and TCGA whole genome sequencing data to collaboratively attain an integrated understanding of cancer by deriving insights across tumor types.

Learn More

SYNODOS

Synodos is a first-of-its-kind Nuerofibromatosis research collaboration dedicated to defeating the rare genetic disorder neurofibromatosis.

Learn More